[Medical oncology].
Patients are more and more often coming to see the physician with reprints from the Oracle of modem times, (the Internet). Facing the rapid development of new anticancer drugs, even the expert can have difficulties in knowing which ones have already rigorous comparative trials and which results are really clinically significant, leading to important improvements in the treatment of patients with solid tumors. In past years we had already noticed that in some cancer types, these progresses unfortunately sometimes remain of marginal importance. Survival benefits are not always well established and, confronted with the exploding costs of medicine, the physician may not always want to use some promising drugs. This review summarizes results of some of the most important randomized clinical trials, but does not attempt to solve the cost-benefit question.
Aapro
M S
MS
IMO, Clinique de Genolier, 1272 Genolier. maapro@genolier.net
D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic